Prognostic value of flotillins (flotillin-1 and flotillin-2) in human cancers: A meta-analysis
Prognostic value of flotillins (flotillin-1 and flotillin-2) in human cancers: A meta-analysis
复制标题
DOI：
10.1016/j.cca.2018.02.036
复制
发表时间：
2018-06-01
影响因子：
5
通讯作者：
Dai, Zhijun
中科院分区：
文献类型：
--
作者：
Deng, Yujiao;Ge, Pengbo;Dai, Zhijun
越来越多的证据表明，与细胞浸润和转移相关的flotillin在多种肿瘤中过表达。flotillins的预后作用仍然存在争议。我们对已发表的研究进行了全面的荟萃分析，以调查flotillin在癌症患者中的预后价值。收集合并的HR（风险比）和95%CI（置信区间）以估计预后价值。最终确定了27项研究（4803例癌症患者）。结果表明：（1）漂浮蛋白升高预测OS较差（总生存期）（HR = 2.17，95% CI 1.87 - 2.52; HR = 1.61，95% CI 1.44 - 1.81）和DFS（无病生存）（HR = 2.41，95%CI 1.83 ~ 3.18; HR = 3.01，95%CI 2.12 ~ 4.27）;（2）亚组分析显示flotillin-1对所研究肿瘤的OS和DFS的预测价值不受肿瘤类型的影响（如消化系统癌症、肾细胞癌、肺癌或其他）、国家（中国或加拿大）、截止值、检测方法、分析类型或纸张质量和flotillin-2过表达指示除鼻咽癌之外的人类癌症中的差OS。Flotillins有望成为预测肿瘤患者预后不良的新生物标志物。这一结论需要更多不同类型癌症的临床研究来证明。
Increasing evidence indicates that flotillins which associate with cell infiltration and metastasis are over expressed in multiple tumors. The prognostic role of flotillins remains controversial. We conducted a comprehensive meta-analysis of published research to investigate the prognostic value of flotillins in patients with cancer. Pooled HRs (hazard ratio) with 95% CIs (confidence interval) were collected to estimate the prognostic value. Twenty-seven studies with 4803 cancer patients were finally identified. The results indicated that: (1) elevated flotillins predicted poorer OS (overall survival) (HR = 2.17, 95% CI 1.87 to 2.52; HR = 1.61, 95% CI 1.44 to 1.81) and DFS (disease-free survival) (HR = 2.41, 95% CI 1.83 to 3.18; HR = 3.01, 95% CI 2.12 to 4.27) in patients with cancer; (2) Subgroup analysis showed that the prognostic value of flotillin-1 on OS and DFS in the investigated tumors were not altered by tumor type (such as digestive system cancers, renal cell cancer, lung cancer, or others), country (China or Canada), cutoff value, detection method, analysis type or paper quality and flotillin-2 overexpression indicates poor OS in human cancers except for nasopharyngeal carcinoma. Flotillins are promising as new biomarkers to predict poor prognosis of patients with tumors. This conclusion needs more clinical studies with different types of cancer to be proven.